Futura Medical PLC Futura Medical - Notice of Interim Results (6806J)
2023年8月18日 - 3:00PM
RNSを含む英国規制内ニュース (英語)
TIDMFUM
RNS Number : 6806J
Futura Medical PLC
18 August 2023
18 August 2023
Futura Medical plc
("Futura" or the "Company")
Notice of Interim Results
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), the
pharmaceutical company developing innovative sexual health products
, will announce its interim results for the six months ended 30
June 2023 on Monday 18(th) September 2023.
The Company will host a webcast for investors and analysts on
the day of the results, which will be made available within the
investor centre section of the Company's website.
A Retail Investor event is scheduled for Tuesday 19(th)
September at 10.00am BST with Investor Meet Company. Retail
Investors can register via www.investormeetcompany.com .
-ENDS-
For further information, please contact:
Futura Medical plc
James Barder, Chief Executive Officer
Angela Hildreth, Finance Director and COO
Email: investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Nominated Adviser and Sole Broker:
Liberum
Phil Walker/ Richard Lindley/ Ben Cryer
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Nick Bastin/ Jonathan Edwards/ Zoe Bolt/ Elena Bates
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 882 9621
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing innovative products based on its proprietary,
transdermal DermaSys(R) technology.
MED3000, the Company's breakthrough treatment for erectile
dysfunction ("ED") has a unique evaporative mode of action and is
clinically proven as an effective topical treatment for adult men
with ED, with a key claim of "Helps you get an erection within 10
minutes". Eroxon(R) is available Over the Counter ("OTC") without a
doctor's prescription. www.eroxon.com .
MED3000 is being manufactured and commercialised under the brand
name Eroxon(R) in regulatory approved countries and is FDA approved
in the US, CE marked in Europe and UKCA marked in the UK and a
growing number of countries across the world. Futura has commercial
agreements with the likes of Haleon for the US market and Cooper
Consumer Health for Europe.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange. www.futuramedical.com
.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORUBUUROBUWAAR
(END) Dow Jones Newswires
August 18, 2023 02:00 ET (06:00 GMT)
Futura Medical (LSE:FUM)
過去 株価チャート
から 10 2024 まで 11 2024
Futura Medical (LSE:FUM)
過去 株価チャート
から 11 2023 まで 11 2024